🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Presented at #ECO2025: In the SURMOUNT-5 phase 3b trial involving adults with obesity without type 2 diabetes, tirzepatide was superior to semaglutide in reducing body weight and waist circumference. Full trial results: nej.md/44ZeMPz EASLnews

Early anticoagulation therapy following surgical bioprosthetic valve replacement. Endoxaban may be a favorable alternative to warfarin. The ENBALV Trial #AHAJournals Yusuke YOSHIKAWA ahajrnls.org/3FaPh3i

🚨 New in #JACCINT: In bifurcation #PCI, proximal optimization + kissing balloon + final POT (PKP) outperforms proximal optimization + side branch dilation + final POT (PSP) with better stent expansion & apposition! 📊 jacc.org/doi/10.1016/j.… #CRABBIS #cvImaging FRANCESCO BURZOTTA

Please have a look at my recently published case report of an educational ECG!! Pre-arrest electrocardiogram changes due to vasospastic angina academic.oup.com/eurheartj/arti…

Coronary Physiological Indices can be used to identify the functional significance of a myocardial bridge in patients with #INOCA Vedant Pargaonkar Hisao Otsuki Kuniaki Takahashi #cardiotwitter #AHAJournals ahajrnls.org/3YRavKr

Huge potential for ASCVD reduction: in women and men a 2 mmol/L (77 mg/dL) lower remnant cholesterol likely reduce 10-year risk of ASCVD by 13–17% & 15–20%, more in statin users than in non-users academic.oup.com/eurjpc/advance… Karen Hvid et al use modelling in CGPS & publish in EJPC

Our partnership with Dr. Glaucomflecken continues as he summarizes recent research into male-partner treatment to prevent recurrence of bacterial vaginosis. Access the article for free: nej.md/DrG17

LATE-Breaking trial @EuroPCR2025 Just published in EuroIntervention! The 4D-ACS trial demonstrates that 1-month DAPT followed by reduced-dose prasugrel monotherapy in ACS patients with drug-coated stents reduced net adverse clinical events by 49%, driven primarily by a reduction

Another de escalation strategy dapt trial

Unguided de escalation of Prasgrel. Similar to HOST RDUCE ACS trial.

In patients with CCS undergoing PCI, ticagrelor monotherapy after 3 months of DAPT showed similar 1-year ischaemic and bleeding outcomes compared to ticagrelor-based #DAPT, regardless of high ischaemic risk status. Mauro Gitto ow.ly/6Afj50VYwKa #EAPCI #TWILIGHTTrial

Cardiovascular health (CVH) declines starting around age 10, with significant sociodemographic disparities influencing CVH trajectories. ja.ma/43LxM2Y Sarah de Ferranti

Statin use is associated with lower risks of hepatocellular carcinoma (HCC) and hepatic decompensation, and improved fibrosis progression in patients with chronic liver disease. ja.ma/3Sgs5np

We have a new Lp(a) paper, led by David Erlinge from PROSPECT 2 using IVUS/NIRS. It shows high Lp(a) associates most with vulnerable plaque characteristics, whereas LDL-C with plaque burden. Lp(a) was measured by our UC San Diego Cardiology assay, the only Lp(a) assay I am aware of that is

アジアNo. 1の循環器病センターで研修したい人、どしどし応募してください。締切間近！ncvc.go.jp/recruit/info/d…

When it rains, it pours - More OBI data. Across 3 phase 3 trials, BROADWAY (obi), BROOKLYN (obi) & TANDEM (obi + ezetimibe), obicetrapib, an oral CETP inhibitor, effectively reduced not only LDL-C, but also Lp(a), especially in those with moderately elevated Lp(a) levels. In

Phase 2 PURSUIT study showed AZD0780 has favorable efficacy and safety, comparable to other #PCSK9 inhibitors, with the added benefit of once-daily oral therapy w/ statin. Supports further development in larger, longer studies. jacc.org/doi/10.1016/j.… #JACC #PCSK9i

SGLT2 inhibitors reduce the risk of renal failure in CKD stage 5 patients with Type 2 DM SGLT2 inhibitors may offer renal protection and did not increase infection risks for CKD5 patients with type2 diabetes nature.com/articles/s4159…

Spontaneous Coronary Artery Dissection: Pitfalls of Angiographic Diagnosis and an Approach to Ambiguous Cases | JACC: Cardiovascular Interventions jacc.org/doi/10.1016/j.…

【募集情報】 令和8年度レジデント・専門修練医・専攻医の募集を開始しました。循環器領域の世界最高峰を目指す #国循 で臨床手技を極めたい、臨床研究に注力したい皆様、ご応募お待ちしています！ 締切：令和7年6月23日（月）17時必着 ⇒ncvc.go.jp/recruit/doctor/ #NCVC